Pharmaceutical Raw Material Telaprevir Powder CAS 402957-28-2 Telaprevir

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A12
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Telaprevir
• Appearance: White Powder
• Assay: 99%
• CAS: 402957-28-2
• OEM: Available
• Sample: Available
• Suitable: Adult
• Function: Inhibits Viral Protease
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	Telaprevir
Synonyms	VX-950;VX-950 (Teleprevir)
CAS No.	402957-28-2
EINECS	N/A
MF	C36H53N7O6
MW	679.85
Appearance	Powder
Moisture	≤0.1%

 

Physicians prescribe the antiviral medication telaprevir in conjunction with peginterferon alfa and ribavirin for the treatment of the hepatitis C virus (HCV). The HCV drug not only increases the likelihood of disabling the virus but also may decrease the amount of time patients require treatment. The treatment regimen may cause anemia and typically produces flu-like symptoms. Telaprevir interacts with many prescribed medications.

1. Treatment of Hepatitis C: Telaprevir is primarily used in the treatment of chronic hepatitis C virus (HCV) infection, specifically genotype 1, which is often more difficult to treat than other genotypes.
2. Combination Therapy: It is administered in combination with peginterferon alfa and ribavirin, enhancing the effectiveness of the treatment regimen by inhibiting viral replication more effectively.
3. Refractory Cases: Telaprevir can be particularly beneficial in patients who have not responded well to previous HCV treatments or have relapsed after treatment.

1. Inhibits Viral Protease: Telaprevir is a direct-acting antiviral (DAA) that specifically inhibits the HCV NS3/4A serine protease, a vital enzyme for viral replication.
2. Blocks Replication Cycle: By inhibiting this protease, telaprevir disrupts the viral replication cycle, preventing the production of new virus particles and reducing viral load in the body.
3. Improves Sustained Virologic Response (SVR): When used as part of a combination therapy, telaprevir has been shown to significantly increase the rates of SVR, which is the absence of detectable HCV RNA in the blood for at least 12 weeks after treatment completion, indicating a cure.